On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
-
REGULATORY 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
-
BUSINESS Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
-
REGULATORY CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
-
REGULATORY Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
-
BUSINESS MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
-
BUSINESS Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
-
ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
-
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts
December 19, 2011
-
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
-
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
-
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
-
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
-
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
-
BUSINESS MTPC to Focus on Development of Global Human Resources
December 14, 2011
-
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
-
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
-
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
-
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
-
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…